# Research Inferences Integration Report — 2026-10-23 **Baseline audit:** [[research/Research Inferences Integration Audit - 2026-09-11|Research Inferences Integration Audit — 2026-09-11]] **Companion audit:** [[research/Research Inferences Integration Audit - 2026-10-23|Research Inferences Integration Audit — 2026-10-23]] **Source register:** [[research/Research Inferences|Research Inferences]] (INF-0001 to INF-0500) **Scan window:** 2026-09-11 through 2026-10-23, with earlier 2025–2026 events included where the vault still lacks them **Disposition:** Discovery pass. This report and its companion audit were the only files written in the discovery pass; every wiki change below was a proposal. Later the same day, the ten Priority 1 nodes of section 5.1 were created on request (see the addendum). **Collection route:** [[collections/Neurotech|Neurotech]] · **Concept router:** [[wiki/Consciousness Mapping and Transfer|Consciousness Mapping and Transfer]] · **Source article:** [[articles/Technologies for Consciousness Mapping and Transfer|Technologies for Consciousness Mapping and Transfer]] --- ## 1. Executive posture The register's architecture holds. Five hundred inferences remain correctly homed, and nothing in the 2026-09-11 to 2026-10-23 record contradicts any of them. What changed is the map of *where* the first approvals arrived, and it changed in a direction the register anticipated without naming. The first market approval for an implanted brain-computer interface came from China's National Medical Products Administration on 13 March 2026 (Neuracle's NEO, cervical spinal-cord injury), and the first CE mark for a commercially launched BCI retinal implant came from Europe on 22 July 2026 (Science Corporation's PRIMA, geographic atrophy). Both precede any FDA premarket approval. INF-0055 described a race for the first PMA as the race for the classification template; the template contest is now multi-jurisdictional, and the vault holds neither event. That is the single largest gap this pass found. Three further currents run through the window: 1. **Speech and inner speech are now product-grade research capabilities across three companies.** Paradromics reported real-time attempted *and imagined* speech from its first Connect-One participant (14 September 2026); Neuralink's VOICE trial showed thought-to-speech in a third participant with a synthesized voice (September 2026); and the Stanford–Emory BrainGate team decoded inner speech behind a thought-password gate (*Cell*, 14 August 2025). Cluster D's privacy and access-control inferences now have working instances. 2. **Capital arrived on the schedule INF-0025 predicted.** Five private rounds between June 2025 and September 2026 put roughly $1.58 billion into five U.S. BCI companies (Neuralink $650 million, Synchron $200 million, Science $230 million, Merge Labs $252 million, Precision $250 million). 3. **Embodied connectome emulation reached the fly.** FlyGM (Tsinghua, March 2026) and Eon Systems (March 2026) drove a simulated fly body from the whole-brain connectome; Eon names the mouse as its next target. INF-0126 and INF-0131 move from demonstration toward pipeline. ### 1.1 Corrections to the first draft of this report The first draft of this file, written earlier on 23 October 2026, contained claims that a verification pass could not sustain. They are corrected here so the next cycle builds on clean ground. | First-draft claim | Verified record | Effect | |---|---|---| | The 850 unresolved labels are "largely built out" | 19 of 850 now resolve to a wiki file (2.2%); the named attractor nodes it listed were never in the 850-label ledger | Ledger remains open; see the companion audit | | Connexus, Endovascular BCI, Closed-Loop Neuromodulation and the UNESCO Recommendation are missing nodes | All exist: [[wiki/Paradromics Connexus\|Paradromics Connexus]], [[wiki/Connexus BCI\|Connexus BCI]], [[wiki/Endovascular Brain-Computer Interface\|Endovascular Brain-Computer Interface]], [[wiki/Closed-Loop Neuromodulation\|Closed-Loop Neuromodulation]], [[wiki/UNESCO Recommendation on the Ethics of Neurotechnology\|UNESCO Recommendation on the Ethics of Neurotechnology]] | Enrich; create none | | Medtronic "exists only as a corporate shell" | No Medtronic file exists in the wiki | Creation candidate | | Synchron completed enrollment in the COMMAND *pivotal* trial in September 2026 | COMMAND is the six-participant early feasibility study; enrollment closed in 2023 (ClinicalTrials.gov NCT05035823, "Active, not recruiting," updated 8 September 2026). Synchron plans to file a pivotal IDE before the end of 2026 | INF-0055 timeline set by the pivotal filing | | The 312-neuroscientist survey appeared in *PLOS One* in August 2026 | Published 24 June 2025 (DOI 10.1371/journal.pone.0326920) | Pre-audit anchor; still absent from [[wiki/State Sufficiency Problem\|State Sufficiency Problem]] | | BrainGate2 home use, the double neural bypass, Apple BCI HID, the Convey letter, Merge–Butterfly, and Science's Series C are post-audit events | All entered the vault before 11 September 2026, through the article's September revision | Confirmation, not new evidence | | Apple is INF-0079; Synchron's nineteen-year arc is INF-0077; "DBS substitution" is INF-0075 | Apple BCI HID is INF-0076 and INF-0077; the nineteen-year arc is INF-0053 (with INF-0475); INF-0075 is rehabilitation and neuroplasticity; INF-0079 is shared autonomy | IDs corrected throughout | | INF-0001, INF-0490 and INF-0492 should be promoted to strongly indicated | All three already carry that tier | Recorded as confirmations | | INF-0476, INF-0488, INF-0493, INF-0497 and INF-0498 are "unresolved" | All five are tiered analytic | Corrected | | Med-X BCI-2035 is the first peer-reviewed DALY-ranked BCI roadmap | It is a DALY-weighted priority ranking by Ning Jiang, Jiayuan He and Xiaohong Sui (9 October 2026); priority of first publication is unverified | Proposed INF-0501 rewritten | | LNP stiffness tuning (proposed INF-0505) is strongly indicated | One in-vitro cancer cell-line study | Retiered to plausible | --- ## 2. Top most likely inferences Ranked by consequence if the inference resolves affirmatively within 24 months. Tier changes are recommendations to the register; the register itself is unchanged. ### 2.1 Recommended tier changes | INF | Current tier | Recommended | Deciding evidence (dated) | |---|---|---|---| | **INF-0465** China runs a parallel program with its own trials, companies and standards | strongly indicated | **established** | Seven-ministry *Implementation Opinions on Promoting Innovation and Development of the BCI Industry* (30 July 2025) with 2027 and 2030 targets; NMPA market approval of Neuracle NEO (13 March 2026); 79.1% non-invasive share across registered Chinese BCI studies (arXiv 2607.07185, July 2026) | | **INF-0083** inner speech is the first genuinely private content to become instrumentable | strongly indicated | **established** | Willett, Kunz, Meschede-Krasa et al., *Cell*, 14 August 2025: inner speech decoded in four participants, up to 74% accuracy; Paradromics imagined-speech patterns (14 September 2026) | | **INF-0386** coupled cognition requires an access-control model, and importing computing practice is the fastest route | strongly indicated | **established** | The same *Cell* study gates decoding behind a silently imagined password recognized at over 98%: the first implemented cognitive access control | | **INF-0096** restored speech uses a model-synthesized voice, making the identity object part biological, part trained artifact | strongly indicated | **established** | Neuralink VOICE participant "Terry" speaking through a synthesized voice reported as Grok-based (September 2026); UC Davis restored-voice work in the BrainGate2 lineage | | **INF-0279** the MIND Act is a study mandate stalled in committee | established | established (reconfirmed) | S.2925 introduced 29 September 2025; no committee action on Congress.gov as of this scan | ### 2.2 Confirmed at current tier, with new anchors | INF | Tier | New anchor | |---|---|---| | **INF-0001** Connexus as a networking device; capability resolves to channels × uptime × egress | strongly indicated | Real-time conversational speech over a wireless link and a live phone call with family (14 September 2026), after the 26 August 2026 FDA letter adding phones, tablets and laptops to Connect-One | | **INF-0025** capital arrives quickly once the value ratio is this wide | analytic | About $1.58 billion across five rounds, June 2025 to September 2026 (Section 4.1) | | **INF-0055** first approval sets the classification template | strongly indicated | Template contest is now three-jurisdictional: NMPA (13 March 2026), EU CE (22 July 2026), FDA pending Synchron's planned pivotal IDE | | **INF-0367** programs migrate toward faster jurisdictions, and trial geography shows where a capability becomes ordinary | strongly indicated | Both first commercial authorizations landed outside the United States | | **INF-0491** the medical indication is the carrier wave | analytic | Every 2026 authorization or IDE rides one: spinal-cord injury (Neuracle), geographic atrophy (PRIMA), ALS and motor neuron disease (Connect-One, VOICE), treatment-resistant depression (Motif RESONATE IDE, April 2026), stroke (CorTec, second Breakthrough designation, 30 August 2026) | | **INF-0492** installed base makes the trajectory irreversible | strongly indicated | Medtronic's own figure of more than 40,000 Percept patients (2025 launch materials; no 2026 update located); Precision reports more than 100 patient procedures across 18 institutions (September 2026) | | **INF-0126** connectome-derived fly simulations predict behavior | established | FlyGM (arXiv 2602.17997, v2 8 March 2026) and Eon Systems' embodied fly (March 2026) close the loop through a MuJoCo body | | **INF-0060** procedural workforce gates deployment volume | plausible | Sichuan's reported provincial target of 3,000 invasive BCI operations per year by 2030 (secondary source) is a workforce target expressed as a number | | **INF-0434** elective preservation yields the best outcomes | plausible | Nectome's whole-pig-brain aldehyde preservation (reported May 2026) and its plan to offer the procedure to terminally ill patients; *MIT Technology Review* survey of Nectome and Sparks Brain Preservation (15 October 2026) | | **INF-0329 / INF-0484** platform approval through umbrella trials | strongly indicated / plausible | FDA draft guidance on the Plausible Mechanism Framework (Federal Register, 25 February 2026); *American Journal of Human Genetics* commentary on an umbrella-of-umbrellas prime-editing platform for seven urea-cycle disorders (2026) | ### 2.3 Held at current tier, with the deciding record named - **INF-0477** (first chronic implant above 10,000 channels): **plausible, held.** The first draft called it a scheduling question; the verified record holds Connexus at 421 channels and no published 10,000-channel chronic device. Deciding record: a peer-reviewed or regulator-filed channel count from Neuralink, Paradromics, or a Chinese high-channel program. - **INF-0479** (mouse-region simulation predicting held-out responses): **plausible, held.** The MICrONS foundation model (*Nature*, April 2025) predicts held-out responses from function; the marker requires a connectome-*derived* model. Eon Systems' stated mouse program is the nearest claimant. - **INF-0017** (cortical visual prosthesis as write-side experiment): **plausible, held.** PRIMA's CE mark authorizes a *retinal* write device; Neuralink's Blindsight had no reported human implant as of 7 October 2026. - **INF-0480** (wetware deployment above 1,000 units): **plausible, held.** A 120-unit Melbourne installation appears in one secondary source only. - **INF-0117** (synaptic strength from morphology): **unresolved, held.** The June 2025 survey gives the field's prior (70.5% favor connectivity and synaptic strength; 45.6% judge memory readout from a static snapshot possible in principle; median 41.0% that memories are decodable from an aldehyde-stabilized cryopreserved brain; median human emulation estimate 2125); paired physiology-and-ultrastructure data remain the settling record. - **INF-0100** (portability of the personal residual is the decade's standards fight, unclaimed): **strongly indicated, held.** No claimant appeared. Apple's BCI HID (May 2025) holds the input layer; ISO/IEC JTC 1/SC 43 holds the reference architecture ([[wiki/ISO IEC 27572 2026\|ISO/IEC 27572:2026]]); the person-state layer remains open. ### 2.4 Near-term resolution watch (next 6–12 months) 1. Synchron pivotal IDE filing (company target: before end of 2026) → INF-0055. 2. First FDA Humanitarian Device Exemption decision for PRIMA → INF-0055, INF-0017. 3. Neuralink peer-reviewed VOICE metrics (latency, vocabulary, accuracy) → INF-0007, INF-0080. 4. A second NMPA invasive-BCI registration (NeuroXess is in a year-long trial) → INF-0465, INF-0352. 5. Eon Systems or FlyGM follow-on to mouse tissue → INF-0479. --- ## 3. Reasonable inferences proposed for the register (INF-0501 to INF-0512) Written in the register's grammar so they can be inserted without rewriting. INF-0501 to INF-0505 revise the first draft's proposals; INF-0506 to INF-0512 are new. **INF-0501** · *Insert:* `wiki/Med-X BCI-2035 Perspective`, [[wiki/Med-X|Med-X]], [[wiki/Brain-Computer Interfaces|Brain-Computer Interfaces]] · *Tier:* analytic — Ning Jiang, Jiayuan He and Xiaohong Sui ranked twelve neurological conditions by urgency, importance and impact using disability-adjusted life years and placed Alzheimer's disease, stroke, depression and anxiety at the top (*Med-X*, 9 October 2026). A DALY ranking is a reimbursement argument written in epidemiological units, and the four named indications are the carriers most likely to fund the next decade of BCI capability. **INF-0502** · *Insert:* `wiki/Vagus Nerve Stimulation`, [[wiki/Networked Body|Networked Body]] · *Tier:* plausible — Wearable auricular and cervical vagus stimulation with AI-driven closed-loop personalization moves adaptation from hardware to model (*Med-X* review, 25 August 2026). Implanted VNS already carries a U.S. depression indication; a wearable clearance would give Cluster M its first non-invasive prescription node. No 2026 FDA clearance for a wearable depression device was located. **INF-0503** · *Insert:* `wiki/Tissue Nanotransfection`, [[wiki/Real-Time Genetic Repair|Real-Time Genetic Repair]], [[wiki/In-Body Regulation and Autonomous Physiology|In-Body Regulation and Autonomous Physiology]] · *Tier:* plausible — Tissue nanotransfection turns accessible skin into a biofactory that releases extracellular vesicles acting beyond the application site (*Med-X* Perspective, 1 June 2026). It is the most surgery-free candidate for INF-0325's body-as-platform architecture; a registered first-in-human study is the deciding record. **INF-0504** · *Insert:* [[wiki/Continuity Evidence Ladder|Continuity Evidence Ladder]], [[wiki/Neurotechnology Ecosystem|Neurotechnology Ecosystem]] · *Tier:* analytic — Across 1,327 correlation analyses in 310 biomedical articles, 1.94% reported confidence intervals and 58.71% omitted sample size (*Med-X*, 22 October 2026). The register's biomedical anchors therefore carry a measurable reporting-quality discount, and anchors with sample size and interval reported deserve heavier weight. **INF-0505** · *Insert:* `wiki/Lipid Nanoparticle`, [[wiki/Real-Time Genetic Repair|Real-Time Genetic Repair]] · *Tier:* plausible — Low-to-intermediate-stiffness lipid nanoparticles improved mRNA delivery in liver, ovarian and lung cancer cell lines through clathrin- and lipid-raft-mediated uptake (*Med-X*, 1 May 2026). If stiffness tunes tropism in vivo, the redosable delivery INF-0334 requires becomes a materials-property search rather than a chemistry search. **INF-0506** · *Insert:* `wiki/Neuracle`, `wiki/NMPA`, [[wiki/Neurotechnology Ecosystem|Neurotechnology Ecosystem]] · *Tier:* established anchor, strongly indicated inference — The first market approval for an implanted BCI (NMPA, Neuracle NEO, 13 March 2026) and the first commercial CE-marked BCI retinal implant (PRIMA, 22 July 2026) both preceded any FDA premarket approval. The classification template INF-0055 describes is being written in Beijing and Brussels first, and U.S. sponsors will file against precedents set abroad. **INF-0507** · *Insert:* `wiki/Inner Speech Decoding`, [[wiki/Semantic Neural Decoding|Semantic Neural Decoding]], [[wiki/Neurorights|Neurorights]] · *Tier:* established — A silently imagined password gated an inner-speech decoder with over 98% recognition, and the same system decoded unprompted counting during a visual task (*Cell*, 14 August 2025). Cognitive access control now exists as an engineering primitive, and its first deployment came from the research team rather than from statute. **INF-0508** · *Insert:* [[wiki/Capital Routing Node|Capital Routing Node]], [[wiki/Neurotechnology Ecosystem|Neurotechnology Ecosystem]] · *Tier:* analytic — Roughly $1.58 billion entered five U.S. BCI companies in fifteen months, with repeated investors across them (Khosla Ventures in Science and Synchron; Lightspeed in Science and Neuralink). Investor overlap at this density is the integration plan INF-0451 describes, readable before any partnership is announced. **INF-0509** · *Insert:* [[wiki/Whole-Brain Emulation|Whole-Brain Emulation]], `wiki/Eon Systems`, [[wiki/FlyWire|FlyWire]] · *Tier:* plausible — Whole-connectome fly controllers driving simulated bodies (FlyGM; Eon Systems, March 2026) convert the species ladder of INF-0141 into a software pipeline: connectome, connectome-constrained dynamics, neuromechanical body. The next rung is a mouse cortical region, and the first group to publish it will hold the INF-0479 marker. **INF-0510** · *Insert:* `wiki/China BCI Industry Implementation Opinions`, [[wiki/China Brain Project|China Brain Project]] · *Tier:* strongly indicated — The national plan targets two or three leading companies by 2030, and secondary reports add provincial quotas (Sichuan, 3,000 invasive BCI operations a year by 2030; Beijing, three to five BCI unicorns by 2027; Shanghai, widespread adoption by 2030) that express installed base as plan quotas, pending primary-text confirmation. Under INF-0492, a planned installed base becomes irreversible on the plan's own schedule. **INF-0511** · *Insert:* [[wiki/Neurorights|Neurorights]], [[wiki/UNESCO Recommendation on the Ethics of Neurotechnology|UNESCO Recommendation on the Ethics of Neurotechnology]], [[wiki/Continuity Governance|Continuity Governance]] · *Tier:* plausible — The UN Secretary-General's October 2026 report recommends treating thoughts as highly sensitive personal data and requiring explicit consent for neurotechnology in investigative, judicial and correctional settings. Read with Human Rights Council resolution 58/6 (April 2025) and the UNESCO Recommendation (November 2025), it is the third UN instrument in eighteen months; market participants should price a criminal-justice consent rule into product roadmaps for justice-sector buyers. **INF-0512** · *Insert:* [[wiki/Neuralink|Neuralink]], [[wiki/xAI|xAI]], [[wiki/Cognitive Interface Layer|Cognitive Interface Layer]] · *Tier:* strongly indicated — A Neuralink speech participant speaking through a voice model from a sister company (reported September 2026) is the first visible composition of implant, decoder and foundation-model voice inside one founder's portfolio. INF-0078 and INF-0490 meet here: the realized bandwidth comes from the model's prior, and the model belongs to the same capital graph as the implant. --- ## 4. Connections among businesses, technologies, people and announcements ### 4.1 Capital wave, June 2025 to September 2026 | Company | Round (date) | Named participants | Vault status | |---|---|---|---| | [[wiki/Neuralink\|Neuralink]] | $650M Series E (June 2025) | ARK, DFJ Growth, Founders Fund, G42, Lightspeed, QIA, Sequoia, Thrive, Valor, Vy | present; a reported ~$500M raise at $8.5B pre-money (October 2026) is unconfirmed | | [[wiki/Synchron\|Synchron]] | $200M Series D (6 November 2025) | [[wiki/Double Point Ventures\|Double Point Ventures]] (lead), ARCH, [[wiki/Khosla Ventures\|Khosla Ventures]], Bezos Expeditions, NTI, METIS | present | | [[wiki/Science Corporation\|Science Corporation]] | $230M Series C (5 March 2026) | Lightspeed, Khosla, Y Combinator, [[wiki/In-Q-Tel\|In-Q-Tel]], Quiet Capital | present | | [[wiki/Merge Labs\|Merge Labs]] | $252M seed (15 January 2026) | OpenAI (largest), Bain Capital, Interface Fund, Fifty Years, Gabe Newell | present | | [[wiki/Precision Neuroscience\|Precision Neuroscience]] | $250M Series D (25 September 2026) | [[wiki/Bill Ackman\|Bill Ackman]] among participants; total raised reported at $430M | **absent; add** | In-Q-Tel's seat in Science's round is a procurement-grade signal: the intelligence community's venture arm is underwriting biohybrid neural interfaces at the commercialization stage, which places Science beside the [[wiki/DARPA N3|DARPA N3]] and [[wiki/IARPA|IARPA]] lineages as a national-capability asset. ### 4.2 Closest connections between new and existing nodes | New or missing node | Closest existing nodes | Edge type | |---|---|---| | `Neuracle` / `NEO` | [[wiki/Tsinghua University\|Tsinghua University]], [[wiki/China Brain Project\|China Brain Project]], [[wiki/Precision Neuroscience\|Precision Neuroscience]] (epicortical comparator) | developed_with; national_program; modality_peer | | `PRIMA` | [[wiki/Science Corporation\|Science Corporation]], [[wiki/Max Hodak\|Max Hodak]], [[wiki/Blindsight\|Blindsight]] | product_of; founder_lineage; competing_visual_prosthesis | | `Inner Speech Decoding` (Willett 2025) | [[wiki/Semantic Neural Decoding\|Semantic Neural Decoding]], [[wiki/BrainGate\|BrainGate]], [[wiki/Stanford University\|Stanford University]], [[wiki/Neurorights\|Neurorights]] | method_of; program; institution; governance_consequence | | `Neuralink VOICE trial` | [[wiki/Neuralink\|Neuralink]], [[wiki/xAI\|xAI]], [[wiki/Grok\|Grok]] | trial_of; voice_supplier (reported) | | `Medtronic` / `Percept and BrainSense Adaptive DBS` | [[wiki/Closed-Loop Neuromodulation\|Closed-Loop Neuromodulation]], [[wiki/Distributed Biological Interfaces\|Distributed Biological Interfaces]], [[wiki/Precision Neuroscience\|Precision Neuroscience]] (reported partnership) | installed_base; cluster_home; partner | | `Med-X BCI-2035 Perspective` | [[wiki/Med-X\|Med-X]], [[wiki/Brain-Computer Interfaces\|Brain-Computer Interfaces]], [[wiki/Motif Neurotech\|Motif Neurotech]] (depression carrier), [[wiki/Cortec\|CorTec]] (stroke carrier) | published_in; ranks; indication_match | | `What are memories made of?` survey (2025) | [[wiki/State Sufficiency Problem\|State Sufficiency Problem]], [[wiki/Brain Preservation\|Brain Preservation]], [[wiki/Whole-Brain Emulation\|Whole-Brain Emulation]] | expert_prior_for; author_cluster; timeline_estimate | | `Ariel Zeleznikow-Johnston` | [[wiki/Brain Preservation\|Brain Preservation]], [[wiki/Digital Afterlife\|Digital Afterlife]] (both already hold his Reminders) | quoted_in; author_of | | `Eon Systems` / `FlyGM` | [[wiki/FlyWire\|FlyWire]], [[wiki/Male Drosophila CNS Quantitative Summary\|Male Drosophila CNS Quantitative Summary]], [[wiki/Whole-Brain Emulation\|Whole-Brain Emulation]], [[wiki/Tsinghua University\|Tsinghua University]] | uses_connectome; emulation_instance; institution | | `Until Labs` | [[wiki/Brain Preservation\|Brain Preservation]], [[wiki/21st Century Medicine\|21st Century Medicine]], [[wiki/Peter Thiel\|Peter Thiel]] (via Founders Fund) | organ_banking_adjacency (INF-0235); capital | | `ARPA-H FRONT` | [[wiki/Brain Preservation\|Brain Preservation]], [[wiki/Real-Time Genetic Repair\|Real-Time Genetic Repair]] | funded_program; cell_replacement (INF-0431) | | `China BCI Industry Implementation Opinions` | [[wiki/China Brain Project\|China Brain Project]], [[wiki/Cyberspace Administration of China\|Cyberspace Administration of China]] | national_policy; regulator_peer | | `UN Secretary-General neurotechnology report (2026)` | [[wiki/UNESCO Recommendation on the Ethics of Neurotechnology\|UNESCO Recommendation on the Ethics of Neurotechnology]], [[wiki/Neurorights\|Neurorights]], [[wiki/UNESCO\|UNESCO]] | instrument_sequence | ### 4.3 People and institutions as the transfer mechanism (INF-0458, INF-0459) - **Sumner Norman and Tyson Aflalo** co-founded [[wiki/Forest Neurotech|Forest Neurotech]] (a [[wiki/Convergent Research|Convergent Research]] focused research organization), co-founded [[wiki/Merge Labs|Merge Labs]], and appear as partners on a £6.5 million ARIA Precision Neurotechnologies award led by [[wiki/Aimun Jamjoom|Aimun Jamjoom]] with the [[wiki/University of Plymouth|University of Plymouth]] (ultrasound for depression, 2025–2028). One pair of people threads a nonprofit, a venture lab, a UK state program and a depression indication; [[wiki/Mikhail Shapiro|Mikhail Shapiro]] adds the Caltech molecular half. - **Max Hodak** carries a Neuralink co-founder lineage into Science Corporation, which now holds Europe's first commercial BCI retinal implant. - **UC Davis** hosts both the BrainGate2 home-use record and a Connect-One site; **Stanford** holds inner-speech decoding (Willett), the mouse visual-cortex foundation model ([[wiki/Andreas Tolias|Andreas Tolias]], [[wiki/Mouse Visual-Cortex Foundation Model|Mouse Visual-Cortex Foundation Model]]) and adaptive-DBS validation. These are the agglomeration sites INF-0463 predicts; trial-site co-location is the readable signal. - **[[wiki/Tsinghua University|Tsinghua University]]** sits behind both Neuracle's NEO and FlyGM, joining China's first commercial invasive BCI and a leading embodied-connectome result in one institution. - **[[wiki/Sam Altman|Sam Altman]]** spans Merge Labs (interfaces), OpenAI (foundation models and Merge's largest investor) and, in earlier reporting, Nectome's waitlist (preservation). Read under INF-0451, the portfolio is a continuity stack in miniature. - **Founders Fund** appears in Neuralink's Series E and led Until Labs' $58 million Series A (September 2025), which spans interfaces and organ-scale cryopreservation in one investor. ### 4.4 Cognitive-OS host positions, restated with verified anchors - **Input layer:** Apple BCI HID (announced May 2025; Synchron iPad demonstration August 2025). - **Egress to consumer hardware:** Paradromics' 26 August 2026 FDA letter (phones, tablets, laptops). - **Bandwidth bet:** Merge Labs (molecular and ultrasound access, OpenAI scientific-foundation-model collaboration, Butterfly Embedded license of 1 September 2026). - **Voice and intent completion:** Neuralink with a sister-company voice model (reported September 2026). - **Regulatory first-mover:** Neuracle under NMPA (13 March 2026). - **Personal-state persistence:** unclaimed (INF-0100). --- ## 5. Missing nodes and missing targets All entries below were checked against the live `wiki/` tree on 23 October 2026 and are absent. ### 5.1 Priority 1: create (each anchors three or more INF statements and a dated primary source) | Proposed node | Why | INF anchors | Primary source | |---|---|---|---| | `Neuracle` (with `NEO` as alias or child) | First market approval of an implanted BCI | 0055, 0367, 0465, 0491, 0506 | [Xinhua, 14 March 2026](https://english.news.cn/20260314/fab8a8e69f004c74a6b40e2d6ae5bc54/c.html) | | `National Medical Products Administration` (NMPA) | Regulator now holding the first invasive-BCI template | 0010, 0055, 0367 | as above; [Bird & Bird analysis (2026)](https://www.twobirds.com/en/insights/2026/china/china-clears-worlds-first-invasive-braincomputer-interface-for-commercial-use-what-the-regulatory-la) | | `China BCI Industry Implementation Opinions` (30 July 2025) | National plan with 2027 and 2030 targets and provincial quotas | 0464, 0465, 0510 | [MERICS brief](https://merics.org/index%2Ephp/de/merics-briefs/manufacturing-metrology-brain-machine-tech-tackling-talent-shortages) | | `PRIMA` (Science Corporation retinal implant) | First commercial CE-marked BCI retinal implant | 0017, 0055, 0367, 0467, 0506 | [Business Wire, 22 July 2026](https://www.businesswire.com/news/home/20260722965902/en/Science-Corp.-Announces-European-Commercial-Launch-of-PRIMA-the-Only-Treatment-to-Restore-Functional-Central-Vision-to-Patients-with-Geographic-Atrophy-Caused-by-Age-Related-Macular-Degeneration-a-Leading-Cause-of-Blindness) | | `Medtronic` and `Percept and BrainSense Adaptive DBS` | Largest installed sensing-BCI base | 0061, 0062, 0064, 0067, 0363, 0492, 0495 | [NeuroNews, FDA approval (2025)](https://neuronewsinternational.com/medtronic-earns-us-fda-approval-of-worlds-first-adaptive-dbs-system-for-parkinsons/); [npj Parkinson's Disease, ADAPT-START (2026)](https://www.nature.com/articles/s41531-026-01269-z) | | `Inner Speech Decoding` (Willett et al. 2025) | Inner speech and thought-password gating | 0083, 0086, 0386, 0507 | [Stanford Medicine, August 2025](https://med.stanford.edu/news/all-news/2025/08/brain-computer-interface.html) | | `Neuralink VOICE trial` | Thought-to-speech with synthesized voice | 0007, 0078, 0096, 0512 | [MobiHealthNews (2026)](https://www.mobihealthnews.com/news/neuralink-brain-implant-helps-man-als-speak-using-his-thoughts) | | `Med-X BCI-2035 Perspective` | DALY-weighted indication ranking | 0491, 0501 | [Med-X article page](https://link.springer.com/article/10.1007/s44258-026-00095-5) | | `What are memories made of?` (2025 survey) | First large-N expert prior for the State Sufficiency Problem | 0117, 0203, 0449 | [PLOS One via PMC, 24 June 2025](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12186944/) | | `Vagus Nerve Stimulation` | Register target since INF-0305; Cluster M's non-invasive entry | 0047, 0305, 0306, 0502 | [Med-X wearable VNS review, 25 August 2026](https://link.springer.com/article/10.1007/s44258-026-00092-8) | ### 5.2 Priority 2: create when the next integration touches the cluster | Proposed node | Rationale | |---|---| | `Ariel Zeleznikow-Johnston` | Two Reminders already cite him; the survey makes him a source author for the sufficiency node | | `Eon Systems` and `FlyGM` | Embodied whole-connectome emulation (March 2026); stated mouse target | | `Until Labs` | Organ-scale reversible cryopreservation, $58M Series A led by Founders Fund (23 September 2025) | | `ARPA-H` and `ARPA-H FRONT` | Register targets since INF-0332 and INF-0456; FRONT funds iPSC-derived neocortical grafts for an estimated 20 million U.S. adults with chronic neocortical damage | | `Tissue Nanotransfection` | INF-0503; Chandan Sen and L. James Lee lineage at Ohio State | | `Lipid Nanoparticle` | Register target since INF-0334; INF-0505 | | `Sonogenetics` | Register target since INF-0026 and INF-0027; Merge Labs' molecular half | | `MIND Act` | Register target since INF-0279; S.2925 text on Congress.gov | | `UN Secretary-General neurotechnology report (2026)` | INF-0511; confirm document symbol before creating | | `Founders Fund`, `ARCH Venture Partners`, `Bezos Expeditions` | Capital-graph nodes for INF-0451 and INF-0508 | | `Speech Neuroprosthesis` | Register target since INF-0002 and INF-0007; currently spread across [[wiki/Semantic Neural Decoding\|Semantic Neural Decoding]] and [[wiki/BrainGate2 home BCI\|BrainGate2 home BCI]] | | `Shanghai Jiao Tong University`, `Springer Nature` | Publisher parents of [[wiki/Med-X\|Med-X]] | | `Casey Harrell`, `David Brandman` | Named participant and implanting surgeon of the BrainGate2 home-use record | ### 5.3 Missing register targets with the heaviest inference load The register's own `Insert` fields name these targets; they remain unresolved and are worth creating as canonical concept homes: `Medical Indication as Carrier` (INF-0491), `Installed Base Effect` (INF-0492), `Channel Count Marker` (INF-0477), `Premarket Approval` (INF-0055), `Percept Neurostimulator` (INF-0061), `BrainSense Adaptive DBS` (INF-0062), `Sonogenetics` (INF-0026, INF-0027), `Vagus Nerve Stimulation` (INF-0305), `Lipid Nanoparticle` (INF-0334). The full 831-label residue is in the companion audit. --- ## 6. Suggested interlinking and node enrichment ### 6.1 Enrich existing nodes (no new file needed) - **[[wiki/State Sufficiency Problem|State Sufficiency Problem]]:** add the 2025 survey as the node's first expert parameter distribution (70.5% connectivity primacy; 45.6% snapshot readout possible in principle; median 41.0% decodable from a cryopreserved brain; median 40.0% emulation without prior recordings, 62% with them; 2045 worm, 2065 mouse, 2125 human), dated 24 June 2025. - **[[wiki/Synchron|Synchron]]** and **[[wiki/Stentrode|Stentrode]]:** add the $200M Series D (6 November 2025) and the planned pivotal IDE filing; record COMMAND as the six-participant early feasibility study closed to enrollment. Treat the "100 patients" and "Home Edition" claims from a single aggregator as unverified. - **[[wiki/Paradromics|Paradromics]]**, **[[wiki/Paradromics Connexus|Paradromics Connexus]]**, **[[wiki/Connect-One|Connect-One]]:** add the 14 September 2026 real-time speech and imagined-speech report, the first implant at University of Michigan Health (17 June 2026), and the three sites (UC Davis, Mass General, Michigan). Enrollment target: two in the registry; ten in one press account (unverified). - **[[wiki/Science Corporation|Science Corporation]]:** add the PRIMA CE mark (22 July 2026, certified by DEKRA, 30 countries), FDA Breakthrough and Humanitarian Use designations, and the Series C participants. - **[[wiki/Precision Neuroscience|Precision Neuroscience]]:** add the $250M Series D (25 September 2026) and the 100-plus procedures across 18 institutions. - **[[wiki/Neuralink|Neuralink]]:** add the VOICE trial participants (Kenneth Shock, January 2026; "Terry," September 2026) and note that Blindsight had no reported human implant as of 7 October 2026. - **[[wiki/Motif Neurotech|Motif Neurotech]]:** add the April 2026 IDE for the RESONATE early feasibility study (DOT stimulator, up to eight centers). - **[[wiki/Cortical Labs|Cortical Labs]]** and **[[wiki/CL1 Biological Computer|CL1 Biological Computer]]:** add the public Cortical Cloud and programming API, the AUD 245,000 Industry Growth Program grant (April 2026), and the Gobi Partners Malaysia investment (March 2026). - **[[wiki/Nectome|Nectome]]** (180 words): add the reported whole-pig-brain preservation (May 2026) and human-offering plan, attributed as company claims. - **[[wiki/Whole-Brain Emulation|Whole-Brain Emulation]]:** add FlyGM and Eon Systems beside the male CNS connectome record. - **[[wiki/Med-X|Med-X]]:** expand `## Relationships` from one edge to the typed routes below. ### 6.2 Typed edges to add | From | Predicate | To | Evidence | |---|---|---|---| | [[wiki/Med-X\|Med-X]] | publishes_priority_ranking | [[wiki/Brain-Computer Interfaces\|Brain-Computer Interfaces]] | BCI-2035 Perspective, 9 Oct 2026 | | [[wiki/Med-X\|Med-X]] | reviews | [[wiki/Networked Body\|Networked Body]] (via `Vagus Nerve Stimulation`) | wearable VNS review, 25 Aug 2026 | | [[wiki/Med-X\|Med-X]] | supplies_delivery_constraint | [[wiki/Real-Time Genetic Repair\|Real-Time Genetic Repair]] | LNP elasticity (1 May 2026); senescence delivery (7 Sep 2026); circular RNA (19 Mar 2026) | | [[wiki/Med-X\|Med-X]] | supplies_platform_candidate | [[wiki/In-Body Regulation and Autonomous Physiology\|In-Body Regulation and Autonomous Physiology]] | TNT Perspective, 1 Jun 2026 | | [[wiki/Med-X\|Med-X]] | audits_reporting_quality | [[wiki/Continuity Evidence Ladder\|Continuity Evidence Ladder]] | correlation Perspective, 22 Oct 2026 | | [[wiki/Neural Interfaces and Continuity Architecture\|Neural Interfaces and Continuity Architecture]] | routes_to | [[wiki/Med-X\|Med-X]] | open *Advances in Brain-Machine Interface* collection, deadline 18 Dec 2026 | | [[wiki/Host–Residual Architecture\|Host–Residual Architecture]] | constrained_by | [[wiki/Apple BCI HID reference\|Apple BCI HID reference]] | INF-0076, INF-0077, INF-0100 | | [[wiki/Semantic Neural Decoding\|Semantic Neural Decoding]] | gated_by | `Inner Speech Decoding` | INF-0386, INF-0507 | | [[wiki/Neurotechnology Ecosystem\|Neurotechnology Ecosystem]] | first_market_approval | `Neuracle` | INF-0506 | | [[wiki/Capital Routing Node\|Capital Routing Node]] | co_invests | [[wiki/Khosla Ventures\|Khosla Ventures]] → Science, Synchron | INF-0508 | | [[wiki/Brain Preservation\|Brain Preservation]] | adjacent_funding | `Until Labs` | INF-0235 | --- ## 7. State-of-the-art developments (verified, dated) | Date | Development | Domain | Vault status | |---|---|---|---| | 24 Jun 2025 | 312-neuroscientist survey on the structural basis of memory, *PLOS One* | sufficiency | quoted in two nodes; survey absent | | 30 Jul 2025 | China's seven-ministry BCI implementation opinions | policy | absent | | 14 Aug 2025 | Inner-speech decoding with password gate, *Cell* | decoding | absent | | 23 Sep 2025 | Until Labs $58M Series A | preservation | absent | | 5 Nov 2025 | Horikawa, mind captioning, *Science Advances* | decoding | present ([[wiki/Semantic Neural Decoding\|Semantic Neural Decoding]]) | | 6 Nov 2025 | Synchron $200M Series D | capital | partial | | 15 Jan 2026 | Merge Labs launch, $252M seed | capital | present | | 25 Feb 2026 | FDA Plausible Mechanism Framework draft guidance (Federal Register) | editing | present in register | | Mar 2026 | FlyGM and Eon Systems embodied fly | emulation | absent | | 5 Mar 2026 | Science Corporation $230M Series C | capital | present | | 13 Mar 2026 | NMPA approves Neuracle NEO | regulation | **absent** | | Apr 2026 | Motif Neurotech IDE (RESONATE) | depression BCI | node present; IDE unconfirmed in node | | May 2026 | Nectome whole-pig-brain preservation (company-reported) | preservation | absent | | 17 Jun 2026 | First Connexus implant, University of Michigan | implants | present | | 22 Jul 2026 | PRIMA CE mark and European launch | regulation | **absent** | | 26 Aug 2026 | FDA letter adding personal devices to Connect-One | egress | present | | 30 Aug 2026 | CorTec second FDA Breakthrough designation | stroke BCI | present | | 1 Sep 2026 | Merge–Butterfly Embedded license | supply chain | present | | 3 Sep 2026 | Male *Drosophila* CNS connectome, *Cell* | connectomics | present | | 14 Sep 2026 | Paradromics real-time and imagined speech | decoding | absent | | Sep 2026 | Neuralink VOICE third participant | decoding | absent | | 25 Sep 2026 | Precision Neuroscience $250M Series D | capital | absent | | 8–9 Oct 2026 | UN Secretary-General neurotechnology report | governance | absent | | 9 Oct 2026 | *Med-X* BCI-2035 Perspective | priorities | listed in [[wiki/Med-X\|Med-X]] only | | 15 Oct 2026 | *MIT Technology Review* on mind-perpetuation ventures | preservation | absent | | 22 Oct 2026 | *Med-X* correlation-misreporting Perspective | evidence quality | listed in [[wiki/Med-X\|Med-X]] only | --- ## 8. Additional research candidates 1. **Neuracle primary documents:** NMPA registration certificate, indication text, NHSA insurance-code assignment (reported within about twelve days; single source), and channel count. 2. **The UN Secretary-General report's document symbol** and its recommendations as adopted text. 3. **The *Med-X* BCI-2035 full text:** the twelve conditions, the scoring weights, and the authors' affiliations (Springer redirected automated retrieval during this pass). 4. **Medtronic's current Percept and BrainSense counts** from 2026 investor materials. 5. **Synchron's pivotal IDE:** ClinicalTrials.gov registration, endpoints, enrollment target. 6. **Neuralink VOICE metrics** and the provenance of the synthesized voice. 7. **Eon Systems' mouse program:** published methods and validation criteria against INF-0479. 8. **Vermont's 2026 privacy law:** whether neural data appears in the enacted text (single vendor source). 9. **Cortical Labs' Melbourne installation:** unit count, against INF-0480. 10. **ARPA-H FRONT awards:** performers and the reported $175 million commitment (single source). 11. **Chinese BCI companies beyond Neuracle:** NeuroXess trial status, StairMed, BrainCo ([[wiki/BrainCo|BrainCo]] exists), with native-language sourcing per INF-0465. --- ## 9. Addendum, later on 23 October 2026 ### 9.1 Priority 1 nodes created The ten Priority 1 rows of section 5.1 were created as eleven files (the Medtronic row split into a company node and a device node that resolves the register target `BrainSense Adaptive DBS`, INF-0062): [[wiki/Neuracle|Neuracle]] · [[wiki/National Medical Products Administration|National Medical Products Administration]] · [[wiki/China BCI Industry Implementation Opinions|China BCI Industry Implementation Opinions]] · [[wiki/PRIMA Retinal Implant|PRIMA Retinal Implant]] · [[wiki/Medtronic|Medtronic]] · [[wiki/BrainSense Adaptive DBS|BrainSense Adaptive DBS]] · [[wiki/Inner Speech Decoding|Inner Speech Decoding]] · [[wiki/Neuralink VOICE Trial|Neuralink VOICE Trial]] · [[wiki/Med-X BCI-2035 Perspective|Med-X BCI-2035 Perspective]] · [[wiki/What Are Memories Made Of (2025 Survey)|What Are Memories Made Of (2025 Survey)]] · [[wiki/Vagus Nerve Stimulation|Vagus Nerve Stimulation]]. Each carries a `## Relationships` section, dated sources, and register statements quoted verbatim with their tiers. Verification during creation refined three points: the national plan's 2030 target is two or three leading companies (provincial quotas are secondary-source); NEO is a Class III approval after 36 procedures across 11 hospitals, co-developed with Tsinghua University (Hong Bo's group); and Neuralink credits a Grok Voice model with the VOICE trial's spoken output (post of 18 September 2026). ### 9.2 Bearing of the new Med-X entries [[wiki/Med-X|Med-X]] gained Volume 1 to 3 entries during this pass. Fifteen of them anchor register inferences; the strongest are listed first. | Med-X entry (date) | Bearing | INF anchors | |---|---|---| | Non-viral gene therapy and genome editing across the blood–brain barrier (11 Jul 2023) | direct anchor for CNS delivery of editors without AAV | 0334, 0339 | | Close-loop therapy with continuous sensing and on-demand drug delivery in the bladder (1 Jun 2025) | a working instance of closed-loop drug delivery | 0317, 0350 | | Comparative efficacy of non-invasive brain stimulation and exercise in MCI and Alzheimer's disease, 79 RCTs (17 Jan 2025) | evidence base for the Alzheimer's carrier in the BCI-2035 ranking | 0491, 0501 | | Toward long-term multimodal intracranial biomarker monitoring with ultrasound metagel sensors (26 Sep 2024) | implant telemetry read acoustically | 0012, 0072 | | Rethink motor cortical control via the experiment–analysis–model flywheel (24 Jul 2025) | model-driven decoding loop; foundation-model logic | 0094, 0103 | | Adhesive bioelectronics for closed-loop therapy (1 May 2025) | compliance matching for chronic interfaces | 0008, 0318 | | Hydrogels in wearable neural interfaces (9 Dec 2024); hydrogel soft bioelectronics (1 Nov 2024) | wearable neural sensing and tissue-matched mechanics | 0008, 0093 | | Intelligent sensing devices for personalized mental health (2 Apr 2025) | passive sensing for the depression and anxiety carriers | 0093, 0352, 0501 | | Wireless passive inductor-capacitor sensors (21 Aug 2025) | battery-free implant sensing | 0018, 0318 | | Flexible and stretchable bioelectronics for organoids (1 Feb 2025) | organoid interfacing instruments | 0140, 0163 | | Towards NeuroAI: neuronal diversity in artificial networks (9 Jan 2025) | typed, cell-diverse models for emulation and neuromorphic design | 0109, 0133, 0184 | | Perspectives on non-genetic optoelectronic modulation biointerfaces (21 Oct 2024) | write access without genetic sensitization, the counterpoint to INF-0034 | 0029, 0034 | | Modulation of the brain extracellular space (3 May 2024) | delivery-path physics for CNS therapeutics | 0339 | | MRI-guided robot intervention (11 Jul 2023) | surgical robotics as throughput asset | 0004 | | Optical in vivo retinal ganglion cell imaging (17 Nov 2025) | imaging the cells PRIMA and other retinal write devices depend on | 0017 | The additions widen Med-X's routes beyond BCI into Cluster M (closed-loop physiology) and Cluster N (delivery), which strengthens the typed-edge proposals in section 6.2. The node itself was mid-edit at the time of reading: its Volume 3 list was written with literal `\n` sequences and a stray `TESTLINE1 TESTLINE2` line, and a `Med-X-BROKEN-BACKUP.md` file sits beside it. Later the same day, on request, [[wiki/Med-X|Med-X]] was rebuilt from that backup with all 93 papers as individual entries threaded to wiki nodes and inferences, and the backup file was removed. --- ## Sources Regulatory and clinical: [Xinhua on Neuracle (14 March 2026)](https://english.news.cn/20260314/fab8a8e69f004c74a6b40e2d6ae5bc54/c.html) · [Bird & Bird on China's first invasive BCI approval](https://www.twobirds.com/en/insights/2026/china/china-clears-worlds-first-invasive-braincomputer-interface-for-commercial-use-what-the-regulatory-la) · [Clinical Translation of BCI in China, arXiv 2607.07185](https://arxiv.org/pdf/2607.07185) · [Science Corp. European launch of PRIMA (22 July 2026)](https://www.businesswire.com/news/home/20260722965902/en/Science-Corp.-Announces-European-Commercial-Launch-of-PRIMA-the-Only-Treatment-to-Restore-Functional-Central-Vision-to-Patients-with-Geographic-Atrophy-Caused-by-Age-Related-Macular-Degeneration-a-Leading-Cause-of-Blindness) · [touchOPHTHALMOLOGY on the PRIMA CE mark](https://touchophthalmology.com/insight/prima-retinal-implant-receives-ce-mark-for-vision-restoration-in-geographic-atrophy/) · [ClinicalTrials.gov NCT05035823 (COMMAND)](https://clinicaltrials.gov/study/NCT05035823) · [ClinicalTrials.gov NCT07357428 (Connect-One)](https://clinicaltrials.gov/study/NCT07357428) · [Paradromics first Connexus implantation (17 June 2026)](https://www.businesswire.com/news/home/20260617963732/en/Paradromics-and-University-of-Michigan-Complete-First-Connexus-BCI-Implantation-for-the-FDA-Approved-Connect-One-Clinical-Study) · [Paradromics real-time speech (14 September 2026)](https://www.businesswire.com/news/home/20260914434545/en/Paradromics-Achieves-Real-Time-Speech-with-Connexus-Brain-Computer-Interface) · [Motif Neurotech IDE (April 2026)](https://patientworthy.com/2026/04/28/motif-neurotech-gains-fda-clearance-to-launch-first-in-human-trial-of-implantable-bci-for-depression/) · [CorTec second Breakthrough designation](https://insights.citeline.com/medtech-insight/device-area/surgery/surgical-procedures/us-fda-grants-cortec-second-breakthrough-device-designation-for-brain-computer-interface-MHQJE3VI6BCLTENQKUSDRSLZV4/) · [Medtronic adaptive DBS FDA approval](https://neuronewsinternational.com/medtronic-earns-us-fda-approval-of-worlds-first-adaptive-dbs-system-for-parkinsons/) · [ADAPT-START, npj Parkinson's Disease (2026)](https://www.nature.com/articles/s41531-026-01269-z) · [FDA Plausible Mechanism draft guidance, Federal Register (25 February 2026)](https://www.federalregister.gov/documents/2026/02/25/2026-03713/considerations-for-the-use-of-the-plausible-mechanism-framework-to-develop-individualized-therapies) · [AJHG on a personalized prime-editing platform (2026)](https://www.cell.com/ajhg/fulltext/S0002-9297(26)00148-5) Decoding: [Stanford Medicine on inner-speech decoding (August 2025)](https://med.stanford.edu/news/all-news/2025/08/brain-computer-interface.html) · [Neuralink VOICE coverage, MobiHealthNews](https://www.mobihealthnews.com/news/neuralink-brain-implant-helps-man-als-speak-using-his-thoughts) · [Teslanorth on the VOICE participant and Grok voice (19 September 2026)](https://teslanorth.com/2026/09/19/neuralink-terry-voice-trial-grok-voice/) · [PsyPost on mind captioning](https://www.psypost.org/mind-captioning-this-scientist-just-used-ai-to-translate-brain-activity-into-text) · [Apple BCI HID and Synchron, Business Wire (May 2025)](https://www.businesswire.com/news/home/20250513927084/en/Synchron-To-Achieve-First-Native-Brain-Computer-Interface-Integration-with-iPhone-iPad-and-Apple-Vision-Pro) Capital: [Neuralink Series E](https://neuralink.com/updates/neuralink-raises-650m-series-e/) · [Synchron Series D, Fierce Biotech](https://www.fiercebiotech.com/medtech/synchron-raises-200m-advance-its-brain-computer-interface-paralysis) · [Science Corporation Series C, Business Wire](https://businesswire.com/news/home/20260305896789/en/Science-Corporation-Closes-%24230-Million-Series-C-to-Accelerate-Commercialization-of-Its-PRIMA-BCI-Retinal-Implant-the-Worlds-Most-Advanced-Vision-Restoration-Technology) · [Merge Labs seed, TechCrunch (15 January 2026)](https://techcrunch.com/2026/01/15/openai-invests-in-sam-altmans-brain-computer-interface-startup-merge-labs/) · [Merge Labs and Butterfly Network partnership](https://ir.butterflynetwork.com/News/press-releases/news-details/2026/Merge-Labs-and-Butterfly-Network-Partner-to-Advance-Ultrasound-Based-Brain-Computer-Interfaces/default.aspx) · [Precision Neuroscience Series D, HLTH (25 September 2026)](https://hlth.com/insights/news/precision-neuroscience-raises-250m-to-advance-layer-7-brain-computer-interface) · [Until Labs Series A, HLTH (23 September 2025)](https://hlth.com/insights/news/until-labs-secures-58m-to-advance-organ-cryopreservation-technology-2025-09-23) · [Cortical Labs grant and launch, IT Brief (April 2026)](https://itbrief.co.uk/story/cortical-labs-cl1-commercial-milestone-after-aud-245k-grant) · [Gobi Partners invests in Cortical Labs, TechNode (4 March 2026)](https://technode.global/2026/03/04/malaysia-based-gobi-partners-invests-in-cortical-labs-expands-biological-computing-hub/) Emulation, connectomics, preservation: [What are memories made of?, PLOS One via PMC](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12186944/) · [FlyGM, arXiv 2602.17997](https://arxiv.org/pdf/2602.17997) · [Eon Systems embodied fly](https://eon.systems/updates/embodied-brain-emulation) · [MICrONS foundation model, ScienceDaily (April 2025)](https://sciencedaily.com/releases/2025/04/250409173116.htm) · [E11 Bio roadmap](https://www.e11.bio/blog/roadmap) · [Nectome pig-brain report, Earth.com](https://www.earth.com/news/entire-pig-brain-preserved-using-technique-that-will-be-offered-to-humans/) · [Six wild ideas for perpetuating your mind, MIT Technology Review (15 October 2026)](https://www.technologyreview.com/2026/10/15/1145819/six-wild-ideas-perpetuating-your-mind-cognitive-immortality/) · [ARPA-H FRONT program](https://arpa-h.gov/explore-funding/programs/FRONT) Governance: [MIND Act, S.2925, Congress.gov](https://www.congress.gov/bill/119th-congress/senate-bill/2925/text/is) · [Risk Management Magazine on state neural-data laws (24 February 2026)](https://www.rmmagazine.com/articles/article/2026/02/24/state-of-mind--the-new-landscape-of-neural-data-privacy-laws) · [Boston Globe on the UN neurotechnology report (9 October 2026)](https://www.bostonglobe.com/2026/10/09/nation/un-warns-against-technology-used-read-citizens-minds/) · [HRC resolution 58/6](https://digitallibrary.un.org/record/4082164/files/A_HRC_RES_58_6-EN.pdf) · [ARIA-funded ultrasound depression project, University of Plymouth](https://plymouth.ac.uk/research/psychology/brain-research-and-imaging-centre/transcranial-ultrasound-stimulation/next-generation-brain-machine-interface-for-whole-brain-input-output) *Med-X* papers are cited from the article list held in [[wiki/Med-X|Med-X]] (distilled from Springer Nature Link on 23 October 2026). --- ## Method note Read in full: the 500-statement register, the 2026-09-11 audit (scope, coverage, ledger and relationships), the first draft of this report, and [[wiki/Med-X|Med-X]], [[wiki/State Sufficiency Problem|State Sufficiency Problem]] and [[wiki/Consciousness Mapping and Transfer|Consciousness Mapping and Transfer]]. Read by section: [[wiki/Neural Interfaces and Continuity Architecture|Neural Interfaces and Continuity Architecture]] (structure and dated claims), [[wiki/Brain-Computer Interfaces|Brain-Computer Interfaces]] (company map and structure), and [[articles/Technologies for Consciousness Mapping and Transfer|Technologies for Consciousness Mapping and Transfer]] (section I, epistemic ledger and appendix outline). The requested `wiki/Interfaces and Continuity Architecture` does not exist and was treated as the Neural Interfaces router. The 850-label ledger was re-resolved by exact and case-insensitive filename match plus frontmatter aliases. Every factual claim in the first draft was checked against a primary or near-primary web source; secondary-only claims are marked as such. Tier labels refer to the inference, never to every anchor inside it. *End of report.*